Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 15.5703
- Book/Share 7.0657
- PB 4.9513
- Debt/Equity 1.1733
- CurrentRatio 0.8673
- ROIC 0.1079
- MktCap 73297582236.5765
- FreeCF/Share 2.2968
- PFCF 15.7089
- PE 21.3948
- Debt/Assets 0.2929
- DivYield 0.0348
- ROE 0.2418
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
3 Dividend Stocks for November 2025
Published: November 04, 2025 by: Morningstar
Sentiment: Neutral
This month's trio includes two ADRs.
Read More
GSK's shares stuck in the middle lane
Published: November 04, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC's (LSE:GSK, NYSE:GSK) latest quarter looked strong enough on pape, but the share price barely moved. The drugmaker has spent much of the past decade trapped between £15 and £18, and Deutsche Bank thinks that pattern is unlikely to change soon.
Read More
Aviva, GSK, Rolls and bitcoin miners: UK investors most trades shares in October
Published: October 31, 2025 by: Proactive Investors
Sentiment: Neutral
Retail investors on two UK platforms poured into a mix of large financials, big tech and crypto-related names and resource security plays in October, according to the latest trading data. On AJ Bell, which offers trading in all UK stocks, plus most of those available in New York and major European exchanges, investor activity showed a tilt toward income and blue-chip names.
Read More
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
Read More
GSK plc (GSK) Q3 2025 Earnings Call Transcript
Published: October 29, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc ( GSK ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare & President of Global Health Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Peter Verdult - BNP Paribas Exane, Research Division Matthew Weston - UBS Investment Bank, Research Division Michael Leuchten - Jefferies LLC, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, …
Read More
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK (GSK) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.27 per share a year ago.
Read More
GSK lifts profit outlook after strong quarter and upbeat broker reaction
Published: October 29, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% to 1,707p after the pharmaceutical group raised its full-year guidance and delivered quarterly results that topped forecasts across almost every metric. The upbeat figures, helped by a strong performance in Specialty Medicines and vaccines, also prompted positive analyst commentary, with Jefferies reaffirming its 'buy' rating and setting a price target of 2,000p.
Read More
GSK Raises Guidance After Sales, Earnings Growth
Published: October 29, 2025 by: WSJ
Sentiment: Positive
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
Read More
GSK hikes outlook as sales and earning grow faster than expected
Published: October 29, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) raised its outlook for the full year after beating expectations with third-quarter revenues and earnings per share. Group revenues for the FTSE 100 drugmaker came in at £8.55 billion for the quarter to the end of September, up 7% on the same period last year and topping the average City forecast of £8.28 billion.
Read More
GSK raises 2025 sales forecast after strong growth in specialty medicines
Published: October 29, 2025 by: Reuters
Sentiment: Positive
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
Published: October 24, 2025 by: Investors Business Daily
Sentiment: Positive
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
Read More
GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Positive
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market sentiment, with growth led by Specialty Medicines and geographic expansion in Europe. Unlike peers, GSK faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples.
Read More
GSK's Hidden Growth Engines Beyond HIV And Oncology
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing by 71% year-on-year. In addition, GSK increased its 2025 sales growth outlook from a "low-double digit percentage" to a "low-teens percentage."
Read More
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc (NYSE:GSK ) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Sachin Jain - BofA Securities, Research Division Presentation Sachin Jain BofA Securities, Research Division Sachin Jain here from the European team, Bank of America. It's my pleasure to be hosting Glaxo.
Read More
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
Read More
GSK commits $30bn to US drug research and manufacturing
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) will pour $30 billion into research, development and manufacturing in the United States over the next five years, in one of the largest overseas investment programmes announced by a UK-listed company. The commitment includes a fresh $1.2 billion package unveiled today to expand production capacity and adopt artificial intelligence and digital technologies across its American operations.
Read More
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
Published: September 17, 2025 by: CNBC
Sentiment: Positive
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
Read More
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
Published: September 16, 2025 by: WSJ
Sentiment: Positive
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
Read More
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
Read More
GSK Adds Around $5B in a Month: Here's How to Play the Stock
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Emma Natasha Walmsley
- Employees 68629